Skip to main content
OpenTrials
Completed

NCT Number: NCT01368185

Impact of MK-0954A on Uric Acid in the Management of Hypertension (MK-0954A-366)

This was a retrospective, chart review, observational study to assess the effect of MK-0954A (losartan potassium 50 mg + hydrochlorothiazide 12.5 mg [Hyzaar(R)]) treatment for a period of at least three months on serum uric acid levels.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertension Cardiovascular Diseases Vascular Diseases

Age range

20 year–75 year

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participant was >20 years and <75 years of age on the index date (i.e., the date of initiating MK-0954A therapy)
  • Diagnosed with hypertension and had received MK-0954A 50/12.5 mg for at least 3 months
  • Had at least one serum uric acid measurements at baseline and one at 3 months after using MK-0954A 50/12.5 mg
  • Had the following records documented in the chart during the data collection period:
  • medical history and co-morbidities (if available)
  • sitting blood pressure, serum uric acid, lipid profile test results before and after using MK-0954A 50/12.5 mg
  • serum electrolytes, serum creatinine, and pre-meal sugar (if available)
  • prescription information of all antihypertensive regimens

Exclusion criteria

  • Had been treated with diuretic or angiotensin-receptor blockers (ARBs) 2 weeks before initiated treatment with MK-0954A 50/12.5 mg
  • Serum creatinine >2 mg/dL

Treatment and study plan

Primary outcomes

  1. Serum Uric Acid (SUA) Level

    Time frame: Baseline and Month 3

    SUA at baseline and Month 3.

Secondary outcomes

  1. The Percentage of Patients With Hyperuricemia

    Time frame: Baseline and Month 3

    Hyperuricemia was defined as SUA >6.6mg/dL in females and >7.7mg/dL in males.

  2. Diastolic Blood Pressure (DBP)

    Time frame: Baseline and Month 3

    DBP at baseline and month 3.

  3. Systolic Blood Pressure (SBP)

    Time frame: Baseline and Month 3

    SBP at baseline and month 3.

Sponsors and collaborators

Lead sponsor

Organon and Co

Industry

Registry information

Official study title

A Retrospective Survey to Evaluate the Impact of Hyzaar on Uric Acid in the Management of Hypertensive Patients in Normal Practice

Important dates

Study start
2008
Primary completion
2010
Study completion
2010
First posted
Jun 7, 2011
Registry last updated
Feb 9, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.